title: Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
mesh_terms: D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000191:economics / Q000627:therapeutic use*; D000069604:Dabigatran; D017277:Drug Approval; D004347:Drug Interactions; D006801:Humans; D020521:Stroke / Q000517:prevention & control*; D014481:United States; D014486:United States Food and Drug Administration; D054556:Venous Thromboembolism / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran